EUCTR2007-007520-17-BE进行中（未招募）不适用
A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Effect of RWJ-800088 on The Prevention of Chemotherapy-Induced Anemia and The Prevention of Chemotherapy-Induced Thrombocytopenia in Subjects with Non-Small Cell Lung Cancer Receiving Gemcitabine and Either Carboplatin or Cisplatin - n/a
Janssen-Cilag International N.V, Turnhoutseweg 30, 2340 Beerse, Belgium0 个研究点目标入组 148 人开始时间: 2008年6月30日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 148
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Men or women, at least 18 years of age
- •2. Histologically confirmed diagnosis of stage IIIB or IV NSCLC
- •3. Presence of measurable disease per RECIST criteria
- •4. Candidate for up to 6 cycles of a 21-day chemotherapy regimen of gemcitabine and either carboplatin or cisplatin
- •5. Body weight > 40 kg
- •6. Hemoglobin =12.0 g/dL, but not exceeding the upper limit of the normal range, with:
- •a. No need for ESAs at randomization
- •b. No history of anemia due to factors other than cancer/chemotherapy (e.g., iron, B12 or folate deficiencies, hemolysis, or bleeding)
- •7. Neutrophil count within normal range
- •8. Platelet count within 100,000 to 450,000/µL
- •9. ECOG Performance Status of 0 or 1 (Attachment 7)
- •10. Creatinine clearance = 40 ml/min, per Cockroft-Gault formula Estimated creatinine clearance (ml/min) = [[140 - age(yr)]*weight(kg)]/[72*serum Cr(mg/dL)]
- •(multiply by 0.85 for women)
- •11. Negative serum ß human chorionic gonadotropin (ßhCG) in women of childbearing potential
- •12. Women must agree to not get pregnant during the study.
- •13. Men must agree to use a double barrier method of birth control and not donate sperm from the first dose of study drug through 30 days after receiving the last dose of study drug.
- •14. Willing to adhere to the prohibitions and restrictions specified in this protocol.
- •15. Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
- •16. To participate in the optional pharmacogenomic component of this study, subjects must have signed the informed consent form for pharmacogenomic research indicating willingness to participate in the pharmacogenomic component of the study (where local regulations permit). Refusal to consent for this component does not exclude a subject from participation in the clinical study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Central nervous system metastases; with the exception of a subject with stable brain metastases following stereotactic radiosurgery (gamma knife).
- •2. Prior treatment by systemic therapy or radiation for Stage IIIB or IV NSCLC
- •3. Prior (within 1 year) adjuvant or neoadjuvant therapy for NSCLC
- •4. Diagnosis of a myeloid malignancy or known history of myelodysplasia
- •5. Hemoptysis, or active bleeding
- •6. Planned nonpalliative radiation during the study. Palliative radiation is permitted, at the discretion of the investigator, if the area being treated is small (<15% of body surface area but no pelvic radiation is permitted or no more than 10% of the bone marrow reserve is irradiated).
- •7. Other malignancies within 5 years prior, except carcinoma in situ of the cervix, or non-melanoma skin cancer.
- •8. Systemic infection within the last 30 days or major infection requiring hospitalization and antibiotics within the last 14 days
- •9. History of thrombovascular event (TVE) within the past 2 years; evidence of acute thromboembolic event in the last 45 days
- •10. Transfusion of platelets or RBCs within 28 days before the planned first dose administration of study medication
- •11. Neuropathy > Grade 1
- •12. Currently receiving therapeutic or prophylactic heparin or low molecular weight heparin anticoagulants (warfarin is permitted) or anti-platelet therapy (aspirin and NSAIDS are permitted).
- •13. Use of growth factors (e.g. G-CSF, GM-CSF, erythropoietins) or IL-11 within 28 days prior to planned first dose of study drug.
- •14. Prior use of Avastin or Erbitux
- •15. Received an experimental drug or used an experimental medical device within 30 days prior to planned first dose of study drug administration.
- •16. Serology positive for hepatitis B surface antigen (HbsAg), hepatitis C antibodies, or human immunodeficiency virus (HIV) antibodies.
- •17. History of life threatening allergic reactions to food or drugs,including those related to RWJ-800088 (e.g., AMG531, rh-TPO or PEG-MDGF).
- •18. Major surgery within 30 days prior to Screening visit and/or planned surgery
- •with a risk of blood loss.
- •19. Employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members of the employees or the Investigator.
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hypercholesterolemia at Moderately High Risk and High Risk for CHD. - Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus AtorvastatiMedDRA version: 9.1Level: LLTClassification code 10020604Term: HypercholesterolemiaHypercholesterolemiaEUCTR2007-004448-60-BEMerck Sharp & Dohme BV1,281
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Statin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia. - Extended Release Niacin/Laropiprant – LipidsHypercholesterolemia or Mixed DyslipidemiaMedDRA version: 9.1 Level: LLT Classification code 10020604 Term: HypercholesterolemiaEUCTR2007-002017-39-DKMerck & Co., Inc.1,250
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Statin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia. - Extended Release Niacin/Laropiprant – LipidsHypercholesterolemia or Mixed DyslipidemiaMedDRA version: 9.1Level: LLTClassification code 10020604Term: HypercholesterolemiaEUCTR2007-002017-39-ATMerck Sharp & Dohme GmbH1,250
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patient with Metabolic Syndrome and Hypercholesterolemia at High Risk for Coronary Heart Disease - NDmetabolic syndrome and hypercholesterolemiaMedDRA version: 6.1 Level: SOC Classification code 10007541EUCTR2006-006497-17-ITMERCK SHARP DOHME1,120
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Statin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia. - Extended Release Niacin/Laropiprant – LipidsHypercholesterolemia or Mixed DyslipidemiaMedDRA version: 9.1Level: LLTClassification code 10020604Term: HypercholesterolemiaEUCTR2007-002017-39-HUMerck & Co., Inc.1,250